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Abstract
BAG-1 is an anti-apoptotic protein that interacts with a variety of cellular molecules to inhibit apoptosis. The mechanisms by
which BAG-1 interacts with other proteins to inhibit apoptosis have been extensively explored. However, it is currently
unknown how BAG-1 expression is regulated at the molecular level, especially in cancer cells. Here we reported to clone a
novel down-regulated BAG-1 expression gene named FLJ20420 using hBAG-1 promoter as a probe to screen Human Hela 59
cDNA library by Southernwestern blot. The FLJ20420 gene encodes a ,26-kDa protein that is localized in both the
cytoplasm and nucleus. We proved that FLJ20420 protein can specially bind hBAG-1 promoter region by EMSA in vivo and
ChIP assay in vivo. Northern blot analysis revealed a low level of FLJ20420 transcriptional expression in normal human
tissues (i.e., brain, placenta, lung, liver, kidney, pancreas and cervix), except for heart and skeletal muscles, which showed
higher levels. Furthermore, enhanced FLJ20420 expression was observed in tumor cell lines (i.e., MDA468, BT-20, MCF-7,
C33A, HeLa and Caski). Knockdown of endogenous FLJ20420 expression significantly increased BAG-1 expression in A549
and L9981 cells, and also significantly enhanced their sensitivity to cisplatin-induced apoptosis. A microarray assay of the
FLJ20420 siRNA –transfectants showed altered expression of 505 known genes, including 272 upregulated and 233
downregulated genes. Finally, our gene array studies in lung cancer tissue samples revealed a significant increase in
FLJ20420 expression in primary lung cancer relative to the paired normal lung tissue controls (p=0.0006). The increased
expression of FLJ20420 corresponded to a significant decrease in BAG-1 protein expression in the primary lung cancers,
relative to the paired normal lung tissue controls (p=0.0001). Taken together, our experiments suggest that FLJ20420
functions as a down-regulator of BAG-1 expression. Its abnormal expression may be involved in the oncogenesis of human
malignancies such as lung cancer.
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Introduction
BAG-1 is a multifunctional protein that plays important roles in
apoptosis, cell survival, transcription, cell motility and prolifera-
tion. In addition, BAG-1 expression is often altered in various
human malignancies, especially in human breast cancer, lung
cancer and cervical cancer [1,2]. Furthermore, BAG-1 expression
has been associated with the prognosis of a variety of human
malignancies, such as breast cancer and lung cancer [3,4,5].
It is thought that the pleiotropic effects of BAG-1 are due to its
interaction with diverse cellular targets. The proteins Hsc70,
Hsp70, Bcl-2 and RAF-1 kinase, as well as nuclear hormone
receptors and subunits of the ubiquitination-proteasome system,
are all known BAG-1- interacting partners. BAG-1 interacts with
Hsp70 via a C-terminal BAG domain which allows it to facilitate
the nucleotide exchange [6,7]. Many functions of BAG-1 in cell
apoptosis and cell survival are dependent on the BAG domain.
Given the role of BAG-1 in a number of different biological
pathways, it is not surprising that deregulated BAG-1 expression is
associated with tumorigenesis.
BAG-1 is expressed as three major isoforms, designated as p50
(BAG-1L), p46 (BAG-1M), and p33 (BAG-1S), as well as one
minor isoform, p29. The apparent molecular masses of the major
and minor isoforms are 50, 46, 33 and 29 kDa, respectively.
Different BAG-1 isoforms have different biological functions in
different cancer cell lines and tissues [8,9]. We have provided
convincing in vitro evidence that the four protein products are
generated from a single mRNA and translated by alternative
initiation from the four different start codons through a leaky
scanning mechanism [10]. Willis and co-workers also demonstrat-
ed that, in vivo, BAG-1S synthesis is dependent on the presence of
an internal ribosome entry segment (IRES) in the 59-UTR of
BAG-1 mRNA. Their studies also showed that the polypyrimidine
tract binding protein 1 (PTB-1) and poly (rC) binding protein 1
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Furthermore, Willis and co-workers also reported that BAG-1
IRES activity was promoted by structural changes mediated by the
PCBP1 and PTB-1 complex [12]. However, the molecules that
regulate BAG-1 transcription, especially in malignant cells, have
not been well studied.
We previously isolated and characterized the human BAG-1
promoter of an 890-bp DNA fragment in the 59 region [13], which
allowed us to study the transcriptional control of BAG-1. Since
BAG-1 is over-expressed in the human cervical cancer cell line
HeLa, we attempted to identify proteins that bind to the BAG-1
promoter by Southwestern blot analysis, using the BAG-1
promoter as a probe to screen the Human HeLa 59 stretch plus
cDNA library, lTripIEx (Clontech). In this study we describe the
molecular cloning and functional characterization of a cDNA that
encodes a novel protein that physically binds to the BAG-1
promoter between 2483 and –433 bp. Sequence comparison in
the human genome bank identified the gene as FLJ20420, which
has no known function. Functional analysis of FLJ20420 revealed
that this protein downregulates BAG-1 expression in lung cancer
cell lines, suggesting that it may play a role in the regulation of
BAG-1 expression in human carcinogenesis.
Results
Molecular Cloning of FLJ20420
We used the BAG-1 promoter region of an 890-bp DNA as a
probe to screen the HeLa cDNA library, lTripIEx, by South-
western blot analysis. After screening more than 5610
6 plaques,
we obtained two tertiary positive clones. A search of the NCBI
database revealed that one of the clones was identical to the Homo
sapiens cDNA termed FLJ20420 (GI: 7020507). The FLJ20420
gene encodes an uncharacterized coiled-coil-helix-coiled-coil-helix
domain containing protein 3 (Chchd3), which shares approxi-
mately 90% sequence homology with the mouse Chchd3 protein
(GI: 62510510), 85% homology with rat Chchd3 (GI: 62646993)
and 99% homology with chimpanzee Chchd3 (GI: 55629442).
The DNA and protein sequences are shown in Figure S1. This
positive clone contains the complete 227-amino acid open reading
frame. Next, we checked the FLJ20420 sequence in the human
genome database and determined that it is located on chromo-
some 7, and has 8 small exons.
In vitro Binding of FLJ20420 Protein to BAG-1 Promoter
The apparent molecular weight of FLJ20420 and GST-
FLJ20420 proteins was determined to be ,26 kDa and
,50 kDa, respectively (Figure S2a). The HisC-FLJ20420 fusion
protein was also translated in vitro using the TNT Quick
Translation kit with linearized pcDNA3.1/HisC-FLJ20420 plas-
mid. Protein expression was confirmed by Western blotting using
an anti-His antibody, which demonstrated an apparent molecular
weight of ,30 kDa (Figure S2b).
We next determined whether the FLJ20420 protein specifically
binds to the BAG-1 promoter in vitro. To this end, the full length
BAG-1 promoter was first separated into several smaller DNA
fragments of sizes ranging between 150 and 230 bp. These
fragments were used in a gel shift assay with the purified GST-
FLJ20420 fusion protein. The positive DNA fragment was
separated once again into oligos between 30 and 50 bp in length.
As shown in Figure 1A, GST-FLJ20420 bound to the BGP3 DNA
fragment (2483 to –433 bp). Furthermore, a competition binding
test also demonstrated that the FLJ20420 protein specifically
bound to the BGP3 region (Figure 1B). These results confirmed
the specific in vitro binding of the FLJ20420 protein to the BAG
promoter. A ChIP assay was then performed to determine whether
FLJ20420 protein can specifically bind to the BAG-1 promoter in
vivo. We first performed immunoprecipitation of crosslinked
protein/DNA with anti-human FLJ20420 antibody, and then
purified DNA was analyzed by PCR using BAG-1 promoter-
specific primers. GAPDH was used as a control for the system
(Figure 1C). As shown in Figure 1D, the PCR product was
observed in the primer of the BAG promoter (BGP1-4), which
amplified a 175-bp DNA fragment at 2513,2338 bp upstream
the BAG-1 promoter region. This region includes the physically
binding region of the BGP3 DNA fragment (2483 to –433 bp) in
vitro, and indicates that FLJ20420 protein directly binds to the
BAG-1 promoter in vivo. This PCR product was also confirmed
by sequencing to be the BAG-1 promoter.
FLJ20420 Expression in Normal Tissues and Tumor Cell
Lines
To determine whether FLJ20420 is expressed in normal tissues,
a Human MTN RNA Blot (Clontech) was used to assess FLJ20420
RNA expression. As shown in Figure 2A, FLJ20420 RNA was
present in most normal tissues, including heart, skeletal, brain,
placenta, lung, liver, kidney and pancreas. However, increased
expression levels were observed in heart and skeletal muscles
(Figure 2A). Furthermore, MTC multiple human cell line cDNA
panels, which included breast cancer cells (MDA468, BT-20 and
MCF-7), cervical cancer cells (C33A and HeLa) and lung cancer
cells (Caski), also exhibited increased FLJ20420 expression levels.
Interestingly, the C33A cell line possessed two FLJ20420 bands.
One of the bands corresponded to the same band size observed in
the other cancer cell lines, while the second band appeared to be
of smaller size (Figure 2B).
Next, the expression of FLJ20420 and BAG-1 in human lung
cancer cell lines was investigated. There were eleven human lung
cancer cell lines studied, which included five adenocarcinoma cell
lines (A549, GLC82, LTEP-2, SPCA-1 and 95C), one squamous
carcinoma cell line (YTLMC-9), three large cell lung cancer cell
lines (NCI-H460, NL9980 and L9981) and two small cell lung
cancer cell lines (SHP-77 and NCI-H446). As shown in Figure 2C,
relative to the other cell lines, the human lung cancer cell lines
NL9980, SHP-77, NCI-H460, 95C and L9981 all exhibited a
higher level of FLJ20420 expression, as determined by real-time
PCR. Conversely, these same cell lines (NL9980, SHP-77, NCI-
H460, 95C and L9981) also demonstrated lower levels of BAG-1
expression compared to higher BAG-1 expression levels in the
remaining cell lines (GLC82, LTEP-2, NCI-H446, SPCA-1 and
YTLMC-9 ) (Figure 2D). The mRNA expression levels of
FLJ20420 and BAG-1 were determined to be inversely related
based on Pearson’s chi-square test. (x
2=0.681, p=0.000).
Furthermore, Western blot analysis was also used to investigate
BAG-1 protein expression in all of the lung cancer cell lines.
Similarly, a higher level of BAG-1 protein was observed in the
lung cancer cell lines GLC82, LTEP-2, SPCA-1, NCI-H446,
YTLMC-9 and A549 (Figure 2E), which corresponded to
increased BAG-1 mRNA expression.
FLJ20420 Decreased BAG-1 Expression in Lung Cancer
Cell Lines A549 and L9981
To characterize the function of FLJ20420, A549 and L9981
cells were co-transfected with pcDNA3.1/FLJ20420 and the BGP-
Luc (BAG-1 promoter) reporter plasmid. Luciferase activity for the
BGP-Luc (BAG-1 promoter) was determined to be 100% upon
transfection of the empty pcDNA3.1 vector. As shown in
Figure 3A, co-transfection of increasing amounts of pcDNA3.1-
A Novel BAG-1 Promoter Transcription Factor
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from the BGP-Luc-(BAG-1 promoter). Specifically, the luciferase
activity of A549 cells was observed to decrease from 100% to
69.16%, while in L9981 cells, luciferase activity decreased from
100% to 77.85% (see Figure 4A for complete data set demon-
strating progressive decrease). Transfection of 0.8 mg pcDNA3.1-
FLJ20420 reduced luciferase activity by 30.84% in A549 cells
(100% vs 69.16%, P=0.007) and 22.15% in L9981 cells (100% vs
77.85%, P=0.014). However, luciferase activity was not affected
by a similar amount of FLJ20420 plasmid on the pGL3-control
and pGL3-Basic vectors (data not shown). Taken together, these
results suggest that expression of FLJ20420 specifically inhibited
the BAG-1 promoter, in vitro.
Next, we designed two distinct FLJ20420 siRNA (siRNA-1, -2)
to knockdown FLJ20420 mRNA and protein expression in the
A549 and L9981 cell lines. At 48 h after transfection with siRNA-
1 and siRNA-2, the transcriptional expression of the FLJ20420
gene was significantly blocked (Figure 3B). Therefore, microarrays
were used to study FLJ20420 mRNA changes in FLJ-siRNA-
transfected A549 and L9981 cells. As shown in Figure 3C, relative
to the scramble control, the expression level of FLJ20420 in both
FLJ-siRNA-1 transfected cell lines was dramatically decreased.
Since the Genechips contained three probes for BAG-1, each
probe was designated as BAG-1 probe-1 (202387_at), -2
(229720_at) and -3 (211475_s_at). BAG-1 expression was
increased in both A549 and L9981 cells that were transfected
with FLJ-siRNA-1, relative to cells transfected with scramble
control siRNA. Real-time PCR analysis confirmed increased
BAG-1 expression levels in A549 and L9981 cells transfected with
FLJ-siRNA-1, compared to negative siRNA-transfected cells (1.56-
fold increase in expression, P=0.046; 1.87-fold increase in
expression, P=0.029, respectively) (Figure 3D). Western blotting
Figure 1. The binding assays of FLJ20420 to the BAG-1 promoter. (A) The BAG-1 promoter was separated into several 30- to 50-bp DNA
oligos, which were used as probes to perform EMSAs with purified GST-FLJ20420 fusion protein (+). Purified GST protein was used as a control (v). (B)
EMSA competition test. Unlabeled specific DNA fragments (i.e., 100 ng and 1000 ng), and not the non-specific fragment (i.e., n1000) effectively
compete for FLJ20420 binding. (C) Immunoprecipitation of crosslinked protein/DNA with anti-acetyl histone H3 antibody was first performed, and
then purified DNA was analyzed by PCR using the control primers (GAPDH). M: DNA ladder; H2O: water; IP: immunoprecipitation with anti-acetyl
histone H3 antibody; N: negative control, immunoprecipitation with normal rabbit IgG antibody; Input: mixed DNA; IP-FLJ: immunoprecipitation with
anti-human FLJ20420 antibody. (D) Immunoprecipitation of crosslinked protein/DNA with anti-human FLJ20402 antibody was first performed, and
then purified DNA was analyzed by PCR using BAG-1 promoter-specific primers (BGP1-4). M: DNA ladder; H2O: water; P: immunoprecipitation with
anti-acetyl histone H3 antibody; N: negative control, immunoprecipitation with normal rabbit IgG antibody; IP: immunoprecipitation with anti-human
FLJ20420 antibody; Input: mixed DNA.
doi:10.1371/journal.pone.0034832.g001
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PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e34832Figure 2. FLJ20420 mRNA expression in different tissues and cell lines. Northern blot analysis of FLJ20420 mRNA expression in human
normal tissues (A) and various tumor cell lines (B). FLJ20420 cDNA was used as a probe. The number on the left side indicates the size of the
molecular mass markers. The same blot was then stripped and re-probed with human actin probe as an internal control. (C-D) Real-time PCR analysis
of FLJ20420 and BAG-1 mRNA expression in lung cancer cell lines. NL9980 cells were used as a calibrator. The expression of FLJ20420 opposed BAG-1
expression in these cell lines. Error bars are representative of an average of 2 triplicate RT-PCR experiments. (E) Immunoblot analysis shows that BAG-1
protein expression corresponds to BAG-1 mRNA expression in the cell lines analyzed.
doi:10.1371/journal.pone.0034832.g002
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PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e34832Figure 3. FLJ20420 down-regulates the expression of BAG-1 in lung cancer cell lines. (A) Luciferase assay with BAG-1 promoter. Luciferase
reporter under the control of the BAG-1 promoter was co-transfected in A549 and L9981 cells with either the pcDNA3.1 parent vector or pcDNA3.1-
FLJ20420 expression plasmid. Luciferase activity for the BAG-1 promoter is set as 100% upon transfection with the empty pcDNA3.1 vector.
Transfection efficiency was determined by co-transfecting the pRL-CMV vector, which encoded the Renilla luciferase gene (0.02 mg). (B) Knockdown
of FLJ20420 expression in A549 and L9981 cell lines. Cells were transfected with either FLJ20420 siRNA-1, -2 or scrambled control siRNA. After 48 h of
transfection, the cells were collected and total RNA was extracted. FLJ20420 mRNA expression was measured by real-time PCR, in triplicate, as
described in the methods section. (C) Microarrays of FLJ20420-silenced A549 and L9981 cells. In both of the FLJ20420-silenced A549 and L9981 cell
lines, FLJ20420 expression was dramatically reduced, while BAG-1 expression increased, in comparison to control transfected cells. (D) BAG-1 mRNA
expression in FLJ204200-siRNA transfected cells, as measured in triplicate by real-time PCR, and described in the methods section. (E) BAG-1 protein
expression in FLJ20420-siRNA transfected cells was detected by Western blotting with anti-BAG-1 antibody at the same time points post-transfection.
Tubulin was used as an internal control.
doi:10.1371/journal.pone.0034832.g003
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was increased in cells transfected with FLJ-siRNA-1, compared to
the negative control cells (Figure 3E). Taken together, these results
demonstrated that the FLJ20420 gene can negatively regulate
BAG-1 expression in A549 and L9981 cells.
The Biological Function of FLJ20420
The possible role of FLJ20420 as a transcription factor was
explored by first studying the subcellular localization of FLJ20420
in HeLa and NIH/3T3 cells by immunofluorescence. As shown in
Figure 4A, FLJ20420 protein localized in both the cytoplasm and
nucleus of the cell, which is consistent with its function as a BAG-1
transcription factor. Next, the subcellular localization of native
FLJ20420 protein was also determined in A549 cells with
monoclonal anti-FLJ20420 antibody (Figure 4B). The results
showed that FLJ20420 protein localized in both the cytoplasm and
nucleus, but mostly in the cytoplasm of A549 cells.
The biological function of FLJ20420 in cell cycle control and
cell viability was also studied by analyzing cell cycle changes in
A549 and L9981 cells transfected with FLJ-siRNA-1. As illustrated
in Figure 4C, 48 h after transfection, 30.4660.83% and
6.34460.549% of FLJ-20420-silenced A549 cells were in S and
G2/M phase, respectively. In contrast, 28.7760.288% and
7.98260.4007% of control cells were shown to be in S and G2/
M phase, respectively (P.0.05). Similar results were also observed
in FLJ20420-silenced L9981 cells compared to control cells (L9981
cells: 19.7560.8905% and 5.0760.264; control cells: 17.8761.2%
and 5.7460.325%, in S and G2/M phase, P.0.05, respectively).
There was no significant difference in cell viability between the
control and FLJ20420-siRNA-transfected cells
(A549:91.50560.544% vs 89.94261.28%, P.0.05;
L9981:96.20861.032% vs 93.04961.269%, P.0.05, respectively)
(Figure 4D). These results indicated that FLJ20420 may not
directly affect the cell cycle. The role of FLJ20420 in apoptosis was
evaluated in FLJ20420-siRNA-transfected A549 and NL9981 cells
treated with various concentrations of cisplatin (DDP) (i.e., 0,
0.625, 1.25, 2.5, 5, 10, 20, 40 mg/mL). After 24 h of DDP
exposure, cell viability was assessed by the MTT assay. The
percent of cell viability following DDP treatment was calculated
based on the total number of untreated cells, as shown in
Figure 4E. Compared to the control siRNA-transfected cells, A549
and L9981 cells transfected with FLJ20420-siRNA showed
enhanced sensitivity to DDP-induced apoptosis, especially at 2.5
and 5 mg/ml DDP (A549:89.96% vs 104.91%, 71.77% vs 91.67%,
p,0.05, respectively; L9981:73.18% vs 91.12%, 65.99% vs
81.37%, p,0.05, respectively). We then determined the occur-
rence of apoptotic cells by Annexin-V FITC flow cytometry. The
data were analyzed by first determining the percentage of
apoptotic cells in the DDP-treated cell population and then
subtracting the percentage of apoptotic cells in the DDP-untreated
cell population. The percentage of apoptotic cells in the DDP-
untreated cells, which were transfected with the control siRNA or
FLJ-siRNA, showed no significant difference (all with less than 5%
apoptotic cells). As shown in Figure 4F, consistent with the cell
viability study, FLJ-siRNA-1 transfected cells exhibited a signifi-
cant increase in sensitivity to apoptosis when treated with 5 mg/ml
DDP, relative to negative control cells (A549:32.4763.21%
apoptotic cells vs 15.8761.56%, p,0.05; L9981:42.4562.56%
apoptotic cells vs 21.5462.45%, p,0.05).
Gene Expression Profile of FLJ20420-silenced A549 Cells
The biological function of FLJ20420 was further investigated by
analyzing the gene expression profile of A549 cells transfected with
FLJ20420-siRNA. Microarray analysis revealed 655 upregulated
genes, including 272 known genes (272/38,500=0.706%) and 384
unknown genes. A total of 619 downregulated genes were
identified, including 233 known genes (233/38,500=0.605%)
and 386 unknown genes, as shown in Table S1 and S2. Further
analysis revealed that many of the differentially expressed genes
were involved in cell signaling pathways, such as: apoptosis,
calcium signaling pathway, cell cycle, cell junctions, cytokine-
cytokine receptor interaction, ECM-receptor interaction, ErbB
signaling pathway, glycolysis/gluconeogenesis, insulin signaling
pathway, Jak-STAT signaling pathway, MAPK signaling pathway,
p53 signaling pathway, TGF-beta signaling pathway, Toll-like
receptor signaling pathway, ubiquitin-mediated proteolysis and
Wnt signaling pathway (details given in Table S3).
Real-time PCR was also used to verify the upregulated and
downregulated genes that were identified by microarray analysis
(total of 32 genes). As shown in Figure 5, the transcriptional
expression of 15 genes including BAG-1, BCL 2L, IGFBP3,
CDC14B, JUND, TRAF3, TGFBR, AKT1, TRAF5, NFKB2,
TNFSF7, TLR3, MAP3K, IGF2R and RAN were significantly
increased compared to control cells (Figure 5A). In contrast, gene
expression levels of TNFAIP2, USP8, RPC32, EIF3S1, EGFR,
TNFSF1B, RRAD, RANTES, TNFRSF10A, NFKB65 and
NFKBIA were unmistakably decreased (Figure 5B). However,
the altered expression of certain upregulated genes (i.e., CXC16,
IL15) and downregulated genes (i.e., USP25, EGF1, ATPase and
CASP3) were not observed by real-time PCR. Therefore, of the 32
analyzed genes, an 84.3% (27/32) concordance in expression was
determined between the microarray and real-time PCR data.
FLJ20420 and BAG-1 Expression in Human Lung Tumor
tissues
Next, we determined the expression of FLJ20420 and BAG-1
genes in primary lung cancer tissues and the corresponding paired
normal controls. Microarray analysis was carried out in 72 paired
lung tissue specimens, which included 29 adenocarcinomas and 43
squamous cell carcinomas. As shown in Figure 6A-D, expression
of FLJ20420 mRNA was significantly higher in primary lung
cancer tissues compared to the paired normal controls (mean:
8.3649 vs 8.1893, P=0.0006). In contrast, lower expression levels
of BAG-1 mRNA were observed in isolated primary lung tumor
Figure 4. Function of the FLJ20420 gene. (A–B) The subcellular localization of FLJ20420 protein. (A) Cells were transiently transfected
with pEF1-HisC-FLJ20420 for 48 h, fixed with 4% paraformaldehyde, and analyzed by immunofluorescence. Monoclonal anti-Xpress
TM antibody
(Invitrogen, CA), at a dilution of 1:500, was used to detect the FLJ20420 fusion protein (green). Phalloidin (Sigma), at a dilution of 1:500, was used to
stain the cell skeleton (red). DAPI (Sigma), at a dilution of 1:5000, was used to stain cell nuclei (blue). FLJ20420 protein expression is apparent in both
the cytoplasm and nuclei of HeLa cells and NIH/3T3 cells. (B) A549 cells were detected by immunofluorescence with monoclonal anti-FLJ20420
antibody at a dilution of 1:1000 to detect the FLJ20420 native protein (green). DAPI (Sigma), at a dilution of 1:5000, was used to stain cell nuclei
(blue). FLJ20420 protein expression is apparent in both the cytoplasm and nuclei of A549 cells, but most in the cytoplasm. (C) Cell cycle analysis was
evaluated by FACS after using PI to stain the cellular DNA. (D) Cell viability assay: 2610
5 cells/well were seeded in 6-well plates and transfected with
specific or control siRNA. After incubation for 48 h, cell viability was determined by the MTT assay. (E) Cells transfected with FLJ20420 siRNA were
treated with cisplatin (0, 0.625, 1.25, 2.5, 5, 10, 20, or 40 mg/ml) for 24 h and then analyzed by the MTT assay. (F) Cells transfected with FLJ20420 siRNA
were treated with cisplatin (5 mg/ml) for 24 h and then analyzed for apoptosis by FACS.
doi:10.1371/journal.pone.0034832.g004
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probe 1:6.7761 vs 7.2078, P=0.00018; probe 2:8.643 vs 8.9676,
P=8.64E-06; probe 3:8.6574 vs 9.0345, P=7.19E-07).
Discussion
Although several proteins are known to regulate BAG-1
expression, (i.e., interleukin-2 (IL-2), interferons (IFNs) and
granulocyte-macrophage colony-stimulating factor (GM-CSF))
none have been shown to bind directly to the BAG-1 promoter
[14,15,16]. To understand the molecular regulation of BAG-1
expression in human cancer, we have identified a cDNA that
encodes a novel BAG-1 transcription factor, termed FLJ20420,
using a protein-DNA fragment interaction cloning technique. The
predicted amino acid sequence of FLJ20420 has no clear similarity
to any other known proteins. Therefore, FLJ20420 may represent
a novel BAG-1-regulating gene.
FLJ20420 is an uncharacterized coiled-coil-helix-coiled-coil-
helix domain-containing protein 3 (Chchd3) that possesses
sequence similarity with mouse Chchd3 (90%; GI: 62510510),
rat Chchd3 (84%; GI: 62646993) and chimpanzee Chchd3 (99%;
GI: 55629442). In addition, comparison of the conserved domain
of FLJ20420 to known proteins in GenBank, has identified
significant homology with DUF737, a protein of unknown
function. These proteins are part of a family with several
uncharacterized mammalian proteins of unknown function. In
2005, by combined proteome analysis and in situ hybridization,
Dreger reported that rat FLJ20420 mRNA exhibited a high level
of expression in the majority of neurons of the dorsal root ganglion
and the spinal cord, as well as in many types of rat brain cells [17].
Quantitative gene expression profiling in a neurodegenerative
mouse model for Huntington’s disease did not find a significant
difference in Chchd3 expression in R6/2 or wild-type mice [18].
Chen et al studied the differential gene expression of interstitial
cells of Cajal in the murine small intestine and showed that
Chchd3 expression is higher in the region of the myenteric plexus
than in the deep muscular plexus [18]. FLJ20420 has also been
found to be a mitochondrial structural protein, where its depletion
promoted mitochondrial loss and autophagy [19]. In our
experiments, we detected a low level of FLJ20420 expression in
human brain, placenta, lung, liver, kidney, pancreas and cervix,
and a very high level of expression in heart and skeletal muscle.
These data are consistent with other reports regarding increased
FLJ20420 expression levels in heart tissue [20]. FLJ20420 has
been speculated to play a role in energy production and
transcription/translation processes in heart muscle, since it is a
part of the PKCe complexes that contain metabolism-, transcrip-
tion-, and translation-related proteins [21] that are known to
regulate cellular metabolism, protein expression and protein
synthesis. Alternation between transcription factor activation and
protein expression is necessary to protect the heart from ischemia
[22].
BAG-1 is a multifunctional protein that interacts with a wide
range of cellular targets including heat shock proteins and some
Figure 5. Real-time PCR analysis of gene expression in A549 cells transfected with FLJ20420 siRNA. Compared to control transfectants,
a log2 signal ratio $ 1o r# 1 was considered to be a significant change in gene expression. (A) The expression level changes of 17 genes shown to be
upregulated by microarray. (B) Downregulated expression levels of 15 genes, as determined by microarray analysis. Among the 17 upregulated genes
detected by microarray analysis, real-time PCR confirmed 15 of these genes to have significant transcriptional expression changes, while 2 did not
show any significant change. Among the 15 downregulated genes detected by microarray analysis, real-time PCR confirmed 12 of these genes to
have significant transcriptional expression changes, while 3 did not show any significant changes.
doi:10.1371/journal.pone.0034832.g005
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several human malignancies, especially in human breast cancer
and cervical cancer. In this study, we demonstrated that the
FLJ20420 protein specifically binds to the BAG-1 promoter and
functions as a negative transcription factor for BAG-1. Co-
transfection of the BAG-1 promoter with FLJ20420 leads to a
decrease in in vitro promoter activity. This result was also
confirmed by knockdown of endogenous FLJ20420 expression
which leads to increased in vivo BAG-1 expression. We also
observed a concordant decrease in BAG-1 expression and increase
in FLJ20420 expression in lung cancer cell lines and the paired
normal tissue controls. These results suggest that FLJ20420
functions as a negative regulator of BAG-1. BAG-1 can be
expressed as four protein products that are generated by
alternative translation initiation from a single transcript. Although
it has been suggested that the four BAG-1 isoforms are translated
by leaky in vitro scanning, other studies have proposed that an
additional mechanism may be involved. Willis and co-workers
have shown that the in vivo synthesis of BAG-1S is dependent upon
the presence of an internal ribosome entry segment (IRES) in the
59-UTR of BAG-1 mRNA [11]. In our studies, only the expression
of BAG-1 isoforms, p50 and p33, were found to be increased in
FLJ20420-siRNA-transfected A549 and L9981 cells, as shown by
Western blot analysis. We did not observe any changes in the
expression of BAG-1 p46 and p29 isoforms in FLJ20420-silenced
cells. Translation of BAG-1 p50, which contains an SV40-like
nuclear localization signal, is initiated at a non-canonical CUG
codon. Furthermore, translation of BAG-1 p33 is dependent on
the IRES in the 59-UTR of BAG-1 mRNA. These data
demonstrate that the expression of the four BAG-1 isoforms is
regulated by multiple mechanisms including leaky scanning and
IRES, which are both tissue-specific. Current studies are
investigating the role of FLJ20420 in the production and function
of different BAG-1 isoforms in various normal and cancer tissues.
The precise biological function of FLJ20420 still remains
unclear. Considering the role of BAG-1 in apoptosis, we did not
find any significant changes in cell cycle or cell viability in FLJ-
20420-silenced A549 and L9981 cells. These data suggest that
FLJ20420 alone may not regulate these events, and also imply that
BAG-1 expression may be controlled by additional transcription
factors. Furthermore, the role of FLJ20420 in tumor apoptosis was
investigated by studying the effect of downregulated FLJ20420 in
cisplatin-treated cancer cells. Unexpectedly, we found that the
FLJ20420-silenced cells were more sensitive to cisplatin-induced
apoptosis. One explanation for this discrepancy is that FLJ20420
may affect apoptosis through other apoptotic proteins, apart from
BAG-1. Mitofilin, a mitochondrial inner membrane protein that
controls crista morphology, may be an example of such a protein.
Figure 6. FLJ20420 and BAG-1 gene expression in lung tumor tissues. Microarray analysis of FLJ20420 (A) and BAG-1 in lung tumor tissues
(B-D), relative to the paired normal lung tissues.
doi:10.1371/journal.pone.0034832.g006
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expression in HeLa cells leads to decreased cell proliferation and
increased apoptosis [23]. Since the FLJ20420 protein is a known
component of mitofilin complexes [24], it may also modulate cell
apoptosis by interacting with these complexes. In addition, other
apoptosis-controlling proteins may be involved in FLJ20420-
regulated apoptosis. Our microarray studies demonstrated that
siRNA-mediated FLJ20420 downregulation altered the expression
of many apoptosis-related genes. For example, the expression
levels of CASP7, MX1 and BOK were all observed to be
upregulated, while the expression levels of OPA1, MCL1,
APPBP2, TNFRSF10A, CFLAR and CASP3 were dramatically
downregulated. Although the expression of many apoptosis-related
genes changed after silencing of FLJ20420, flow cytometry analysis
did not reveal a clear difference in the percentage of apoptotic cells
between FLJ20420-siRNA and negative control-siRNA transfec-
tants. However, FLJ20420-silenced cells were more sensitive to
cisplatin-induced apoptosis. These data suggest that downregula-
tion of FLJ20420 expression alone is not sufficient to induce
apoptosis, but is sufficient to sensitize cells to apoptosis-inducing
agents such as cisplatin.
Recent studies have demonstrated that Chchd3 is a novel PKA
substrate in mitochondria [25]. Chchd3 contains an N-terminal
myristylation site followed by a domain of unknown function
(DUF) and a CHCH domain (coiled-helix-coiled-helix domain).
The N-terminus of Chchd3 is highly conserved within vertebrates,
and contains a well conserved PKA phosphorylation site at Thr10
or Ser10. Chchd3 is also known to localize to the matrix space in
mitochondria. Mitochondrial proteomic analysis has shown that
FLJ20420 is expressed in the mitochondria [26], while expression
quantitative trait loci (eQTL) analysis of genome-wide gene
expression profiling suggests that FLJ20420 may play a role in
oxidative phosphorylation [27]. Other studies have reported that
FLJ20420 is a lipid raft-associated protein that is involved in
triggering the activation of T-cell antigen receptors [28]. Until
now, the exact physiological role of FLJ20420 has remained
largely unknown. In this study, we have clearly identified the role
of FLJ20420 as a BAG-1 transcription factor, and also linked its
expression to sensitivity to cisplatin-induced apoptosis in cancer
cells. Knockdown of FLJ20420 expression significantly increased
the expression of BCL-2L, IGFBP3, CDC14B, JUND, TRAF3,
TGFBR, AKT1, TRAF5, NFKB2, TNFSF7, TLR3, MAP3K,
IGF2R and RAN, but decreased the expression of TNFAIP2,
USP8, RPC32, EIF3S1, EGFR, TNFSF1B, RRAD, RANTES,
TNFRSF10A, NFKB65 and NFKBIA. Interestingly, many of
these proteins are known to be involved in apoptosis. Nevertheless,
ongoing studies in our laboratory are focused on determining
whether FLJ20420 directly or indirectly regulates the expression of
these genes. In addition, knockdown of FLJ20420 expression also
significantly increased the expression of PRKCBP2, TGFBR1,
TGFB2, CLCN4, TRAF3, MYLK and ACTA2, while decreasing
the expression of SMAD5 and prot-LBC, resulting in an increased
apoptotic potential in FLJ20420-silenced lung cancer cells. This
observation, which is consistent with previous reports identifying
FLJ20420 as a novel PKA substrate in mitochondria, also helped
to connect FLJ20420 with the PKA signaling pathway [25]. Future
studies in our laboratory will investigate the molecular mechanism
that allows FLJ20420 to upregulate the expression of PRKCBP2,
TGFBR1, and TGFB2 and to downregulate the expression of
SMAD5 and prot-LBC.
In these studies, FLJ20420 was observed to be expressed at low
levels in the majority of normal tissues. Interestingly, this is the first
report demonstrating a significant increase in FLJ20420 expres-
sion in primary lung tumors, relative to paired normal lung tissues.
In contrast, BAG-1 expression in primary lung tumor tissues was
found to be significantly lower than in the paired normal lung
tissues. We also demonstrated an inverse relationship between the
expression of FLJ20420 and BAG-1 in lung tumor tissues. Due to
the small number of tissue specimens and short follow-up time, we
were unable to analyze the relationship between FLJ20420
expression and other clinical parameters such as stage, differen-
tiation, response to treatment and survival. We previously reported
that BAG-1 overexpression in a large number of lung cancers is
linked to improved patient prognosis [29]. Future studies at our
institution will determine whether increased FLJ20420 expression
can also be found in the lung cancer patient population.
Additionally, BAG-1 expression is also known to be regulated by
other proteins such as IFNs, IL-2 and GM-CSF. It will be
interesting to determine the expression of these cytokines in these
paired lung cancer and normal tissue samples, to correlate their
expression to FLJ20420 and BAG-1 expression, and also to
analyze their expression in a large number of lung cancer patient
samples. A deeper understanding of FLJ20420 in lung cancer and
other malignancies is important in the development of BAG-1-
targeted therapy to improve the prognosis and treatment of
patients with cancer.
In summary, this is the first identification and characterization
of a negative BAG-1 regulating transcription factor. Our studies
demonstrated that FLJ20420 specifically binds to the BAG-1
promoter and decreases its expression. Our data also suggest that
FLJ20420 plays an important role in apoptosis and oncogenesis in
lung cancer. Current studies in our laboratory seek to unravel the
mechanisms by which FLJ20420 regulates the expression of BAG-
1 and its isoforms, as well as additional apoptotic-related proteins
in lung cancer and other malignancies.
Materials and Methods
Screening of the Human HeLa 59-stretch Plus cDNA
Library, lTripIEx, with the BAG-1 Promoter
BAG-1 promoter probes of different sizes have been previously
reported [13]. The Human HeLa 59-stretch plus cDNA library,
lTripIEx, was purchased from Clontech. Screening of the cDNA
expression library was performed using the Southwestern blot
method, previously described by Vinson et al [30]. Positive
plaques were identified and re-screened until they were homoge-
neously positive. We then converted homogeneously positive
plaques from the lTripIEx to pTripIEx according to the
manufacturer’s instructions. The positive plaque was then
sequenced. Homology searches were performed using BLAST
(Basic Local Alignment Search Tool) from the National Center for
Biotechnology Information (NCBI) available at http://www.ncbi.
nlm.gov.
Cell Culture, Transfection, Immunofluorescence and
Gene Silencing
Human cervical cancer cell line HeLa, NIH/3T3 (mouse
embryonic fibroblast cell line), A549 (human lung adenocarcino-
ma cell line), NCI-H460 (human large cell lung cancer), NCI-
H446 and SHP-77 (human small cell lung carcinoma cell lines)
were from the American Tissue Culture Collection (ATCC). 95 C
(human lung carcinoma cell line), 95 D (human lung carcinoma
cell line) were purchased from the Chinese Academy of Sciences
Committee Cell Culture Collection. SPCA-1,YTMLC-9, GLC-
82, LTEP-a-2 were produced in our institution. Human large cell
lung cancer cell lines L9981 and NL9980 were established by our
institute [31]. HeLa and NIH/3T3 were maintained in DMEM,
and the rest of cell lines were maintained in the RPMI 1640
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CO2. DNA transfection was performed using the Lipofectami-
ne
TM 2000 reagent (Invitrogen, CA), according to the manufac-
turer’s instructions.
Immunofluorescence studies were conducted by seeding 1x10
4
cells/well on 4-well BD Falcon
TM Culture Slides (BD Biosciences)
as previously described by Lu et al [32]. The slides were then
incubated overnight at 37uC with 5% CO2. Transfections were
carried out by mixing 0.6 mg pEF1-HisC-FLJ20420 with the
Lipofectamine
TM 2000 reagent into Hela and NIH/2T3 cells. The
transfection mixture was added to the cell monolayer and the cells
were incubated for an additional 48 h. The washed cells were
incubated with the monoclonal anti-Xpress
TM antibody (Invitro-
gen, CA) at a dilution of 1:500, for 2 h at room temperature and
then with the secondary antibody, Cy
TM2-conjugated AffiniPure
goat anti-mouse IgG (H+L) (Jackson ImmunoResearch Laborato-
ries, green fluorescence), at a dilution of 1:200, for another 2 h at
room temperature. The cytoskeleton and nuclei were visualized by
staining with phalloidin (Sigma, red fluorescence) and DAPI
(Sigma, blue fluorescence) at dilutions of 1:500 and 1:5000,
respectively. The same experiment was performed in A549 cells
with the monoclonal anti-FLJ20420 antibody, purchased from the
Santa Cruz Biotechnology.
Knockdown of FLJ20420 protein expression was performed
using the FJL20420 specific siRNAs (Cat#: siB0892790128 and
2005815122147, Guangzhou Ribobio CO., LTD, China). The
FLJ 20420 siRNA sequences were as follows: FLJ-siRNA-1: sense:
59-GAGCAAGCCAAG AAAGAAU dTdT-39, anti-sense: 59-
dTdTCUCGUUCGGUUCUUUC UUA-39; FLJ-siRNA-2:
sense: 59-GCGGUAUUCUGGUGCU UAU dTdT-39 and anti-
sense: 39-dTdTCGCCAUAAG ACCACGAAUA-59. Scrambled
siRNA, a functional non-targeting siRNA provided by the same
company, was used as a negative control. Briefly, in a 6-well plate,
2610
5 A549 or L9981 cells/well were transfected with 100 pmol
of FJL20420 siRNA or control siRNA using Lipofectamine
TM
2000 (Invitrogen). After incubation at 37uC with 5% CO2 for
48 h, the cells were collected and prepared for analysis by real-
time PCR and Western blotting.
Construction of Recombinant Plasmids
Unless otherwise stated, all plasmids were constructed by
inserting the sequence shown below, between the EcoRI and XhoI
sites. The primers used were: forward 59-gc gaa ttc atg ggt ggg acc
acc agc acc cg-39; reverse 59-gtc ctc gag tta tcc tcc ctt ctc aag cat-
39. PCR amplification of the positive pTripIEx-plaques was used
to generate the regions inserted into the pcDNA3.1-FLJ20420,
pcDNA3.1/HisC-FLJ20420, pEF1-HisC-FLJ20420 and pGEX-
4T-1-FLJ20420 constructs. All constructed plasmids were con-
firmed by DNA sequencing.
FLJ20420 Protein Induction and in vitro Translation
The pGEX-4T-1-FLJ20420 construct was grown in BL21 cells,
and induced with 0.1 mM IPTG at 18uC overnight. The GST-
FLJ20420 fusion protein expressed was purified using the
MicroSpin GST purification module (Amersham). The TNT
Quick Coupled Transcription/Translation kit (Promega) was used
to translate the HisC-FLJ20420 fusion protein from the vector
pcDNA3.1/HisC-FLJ20420, which was then subjected to Western
blot analysis with monoclonal anti-His antibody (Invitrogen).
Electrophoretic Mobility Shift Assays (EMSA)
EMSAs were carried out according to the protocol described by
Chen et al [33]. Briefly, the full-length BAG-1 promoter was first
separated by PCR into several DNA fragments of approximate-
ly150-200 bp in length (primer sequences are available upon
request). The positive DNA fragment was then separated into
smaller fragments until 30-50 bp oligos were obtained. Each
oligonucleotide possessed 10 bp of overlapping sequence. Unla-
beled specific and non-specific oligonucleotides were included at
concentrations of 10, 100, and 1000 ng/40 ml.
Chromatin Immunoprecipitation (ChIP) assay
The ChIP assay was performed using the EZ-Chip Chromatin
Immunoprecipitation kit from MILLIPORE according to the
manufacturer’s instructions. Briefly, crosslinking of protein and
DNA was achieved by treating the Hela cells with 1%
formaldehyde and then with lysis buffer containing protease
inhibitor cocktail. Sonication to shear DNA was done using the
VCX130 (Sonics&Materials, Newtown, USA) at 30% amplitude,
10-s pulses, 40-s rest, 12 times. Immunoprecipitation of crosslinked
protein/DNA was performed with the polyclonal anti-human
FLJ20420 antibody (SIGMA-ALDRICH, St. Louis, USA) at 4uC
overnight. The protein/DNA complexes were eluted to uncouple
the proten/DNA complexes to free the DNA, which was purified
by spin columns. The full length BAG-1 promoter was separated
as a 200-bp DNA fragment. The positive PCR primers that
amplified 2513 ,2338 bp (175 bp DNA fragment) upstream of
the BAG start codon are as follows: BGP1-4F: TCA-
GAGGTCCTGAG CCTACT, BGP1-4R: GGAGT-
GACTCTGCTTCCGTTT.
Luciferase Assays
The pGL3-BGP1 BAG-1 full-length promoter plasmid was used
as previously described [13]. The pGL3-Control (Promega) was
used as a positive control. A549 and L9981 cells were co-
transfected in 6-well plates (5610
4 cells/ml) with 0.8 mg luciferase
reporter, 0.4 mg pcDNA3.1-FLJ20420, and 0.4 mg control vector,
pcDNA3.1 (+). Transfection efficiency was determined by co-
transfection of the pRL-CMV vector (0.02 mg) which encodes the
Renilla luciferase gene. Cells were harvested after 48 h of
incubation and luciferase activity measured using the Dual-
luciferase assay reagent (Promega).
Patients and Tissue Specimens
We studied the frozen specimens of lung cancer tissues and their
paired normal lung tissues from over 2 cm away from the tumor
sites. Seventy-two patients who underwent surgical resection for
non-small-cell lung cancer (NSCLC) at the Tianjin Medical
University General Hospital between December 2006 and August
2008 were included. As shown in Table 1, of these 72 patients, 29
specimens were adenocarcinomas, and 43 specimens were
squamous-cell carcinomas. All of the specimens were diagnosed
on the basis of histologic and immunohistologic criteria, according
to the current World Health Organization (WHO) classification.
The specimens were stored in liquid nitrogen. This study was
approved by the Review Board of Tianjin Medical University
General Hospital.
RNA Isolation and Northern Blotting
Total RNA was extracted from 10
7 cells or 100 mg tissue using
the Trizol reagent (Invitrogen), according to the manufacturer’s
instructions, and quantified by UV spectrophotometry (Beckman
Coulter). Northern blot analysis was performed as previously
described [14] using
32P-dCTP-labeled human FLJ20420 cDNA
as a probe. Human MTN
TM Blot was purchased from Clontech
(Mountain View, CA). Human b-actin cDNA was used as an
internal control.
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Total RNA (2 mg) was reverse-transcribed using the M- MLV
Reverse Transcriptase kit (Promega), according to the manufac-
turer’s protocol. Twenty nanograms of the resultant cDNA were
mixed with the ABI SYBR Green Master Mix (ABI) as well as the
gene primers, and then amplified with the ABI7500 Real-time
PCR System, according to the manufacturer’s protocol. Each
experiment was run in triplicate. The results were analyzed by
comparison of the 2
–averageDDCT. The primers used for real-time
PCR are as follows: FLJ20420 forward: 59-ACGAGAATGA-
GAACATCACCG-39, FLJ20420 reverse: 59-CAGCTCCT-
CAGCTACTCTTC-39; BAG-1 forward: 59-GGCATTCC-
TAGCCG AGTGTG-39, BAG-1 reverse: 59-
CCAGGGCAAAGTTTGTAGACTG-39. PGK-1 was used as
an internal control, as previously described [34].
Microarray Assay
The Human Genome U133 Plus 2.0 microarray, with 54,000
probe sets was purchased from the Affymetrix (Lot #: 4032359).
Total RNA was extracted with the Trizol reagent (Invitrogen) from
the FLJ20420-siRNA transfected cells, negative control cells, or
patients’ lung tissue samples (i.e., primarylung tumor tissues and the
corresponding paired lung tissues). The RNAextracted was purified
using the Oligotex mRNA Midi kit (Qiagen). Microarray assay was
previously described [31]. In the screening process, the genes were
considered to be differentially expressed if the log2 signal ratio was
$1 (upregulated) or #1 (downregulated) [35].
Western Blot Analysis
Cells were homogenized in RIPA buffer (50 mM Tris-HCl,
pH 7.4; 150 mM NaCl; 1% Nonidet P-40; 0.5% sodium deoxycho-
late; 0.1% SDS; 1 mM EDTA; 1 mM PMSF; 1 mg/ml aprotinin).
The protein concentrations were measured using the bicinchoninic
acid (BCA) protein assay kit (Pierce). Twenty micrograms of whole-
cell lysate were separated on a 10–15% SDS-PAGE gel, transferred
to a nitrocellulose (NC) membrane (Amersham Biosciences) and
immunoblotted with a monoclonal anti-b-actin antibody purchased
from Sigma-Aldrich and monoclonal anti-BAG-1 antibody obtained
from the Santa Cruz Biotechnology.
MTT Assay
After transfection with NEG or FLJ20420 siRNA for 48 h in 6-
well plates, the cells were trypsinized and seeded in 96-well plates
at 1610
4/well. They were then exposed to an increasing
concentration of cisplatin ranging from 0 to 40 mg/ml for 24 h.
Twenty microliters of MTT solution was added to each well, and
the cells were incubated for 4 h at 37uC to allow MTT to be
converted to formazan crystals by reacting with metabolically
active cells. Subsequently the formazan crystals were solubilized by
150 ml of DMSO. The absorbance of each well was measured with
a microplate reader at 490 nm (A490).
Flow Cytometry Analysis of Cell Cycle and Apoptosis
Flow cytometry was used to determine the effect of FLJ20420
on the cell cycle. First, 2610
5 cells/well were seeded in 6-well
plates and incubated for 12 h. Cell synchronization was achieved
by starvation in serum-free RPMI-1640 medium for 24 h.
Afterwards, the cells were then transfected with the indicated
siRNA and incubated for 48 h. The cells were then harvested and
fixed in ice-cold 70% ethanol overnight. The cells were treated
with DNase-free ribonuclease (TAKARA), stained with propidium
iodide (PI) (Sigma-Aldrich), and then subjected to a FACSAria
TM
flow cytometry (Becton Dickinson). The data were analyzed with
the ModFit LT software.
Detection of annexin V binding to apoptotic cells was used to
determine the effect of FLJ20420 siRNA on cell apoptosis. First,
2610
5 cells/well were seeded in 6-well plates and transfected with
either FLJ20420-siRNA or control siRNA. The cells were then
treated with 5 mg/ml cisplatin for 24 h, stained using the Annexin
V-FITC Apoptosis Analysis kit (Pharmingen) and subjected to
FACStar plus flow cytometry (Becton-Dickenson) to sort out the
annexin V-FITC-stained apoptotic cells. The data were analyzed
by first determining the percentage of apoptotic cells in the treated
cell population and then subtracting the percentage of apoptotic
cells in the untreated control cell population.
Statistical Analysis
Data are presented as the mean6SD. The t-test was used to
analyze the differences between the negative control and the
FLJ20420-siRNA-transfected groups, as well as the differences
between the lung cancer tissues and the paired normal lung tissue
controls. All of the tests were two-sided. A P value of ,0.05 was
considered statistically significant.
Supporting Information
Figure S1 Sequence analysis of positive cDNA clone and
the deduced amino acid sequence. Numbers indicate
nucleotide positions.
(TIF)
Figure S2 Expression of FLJ20420 fusion protein. (a)
GST-FLJ20420 fusion protein was induced in BL21 cells with
0.1 mM IPTG at 18uC overnight. Lane M contains SeeBlue plus2
standard protein marker (Invitrogen); protein extractions for Lanes
1 and 2 were from uninduced or induced pGEX-4T-FLJ20420-
transformed BL21 cells, respectively; lane V consists of the positive
control for the GST vector. (b) The His-FLJ20420 fusion protein
was translated in vitro using the TNT Quick Translation kit
Table 1. Patient characteristics.
Type Sub-type N (%)
Gender Male 55(76.4%)
Female 17(23.6%)
Age .=61 37(51.4%)
,61 35(48.6%)
Differentiation low 21(29.2%)
medium 31(43.1%)
high 16(22.2%)
mixed 4(5.6%)
Histology adenocarcinoma 29(40.3%)
Squamous cell carcinoma 43(59.7%)
Stage I 14(19.4%)
II 10(13.9%)
III 43(59.7%)
IV 5(6.94%)
Metastatic status none 20(27.8%)
Yes 52(72.2%)
Smoking status Never 20(27.8%)
Smoker 52(72.2%)
doi:10.1371/journal.pone.0034832.t001
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antibody.
(TIF)
Table S1 The upregulated genes in A549-FLJ-siRNA
cells.
(XLS)
Table S2 The downregulated genes in A549-FLJ-siRNA
cells.
(XLS)
Table S3 The differentially expressed genes involved in
cell signaling pathways in FLJ20420-silenced A549 cells.
(DOC)
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